AAM Calls for Clarifications in Supply Chain Waiver Guidance

The Association for Accessible Medicines urged the FDA to clarify its draft guidance on Drug Supply Chain Security Act (DSCSA) waivers by adding an estimated timetable for review decisions.
Source: International Pharmaceutical Regulatory Monitor